Smith & Nephew is an industry leader in each of our three main Global Business Units - Orthopaedic Reconstruction and Trauma, Endoscopy and Advanced Wound Management. These businesses jointly offer over 1,000 product ranges.
Our global infrastructure continues to expand each year. We currently operate in 32 countries and generate annual sales of $3.4 billion. Substantial investment in our products and intensive research and development means that we are always ahead. Figures from last year show that we stand at number one as the leading company in Arthroscopy. We are the second largest organisation in Advanced Wound Management and number three in Trauma and Clinical Therapies. We are also positioned at number four in reconstruction.
Smith & Nephew has a track record of bringing innovative new products to market that provide better clinical outcomes for patients and save costs for healthcare providers. This is the primary focus of our fourth business unit, Biologics.
Closing share price
|FY, 2013||FY, 2014||FY, 2015|
|£2.9 b||£3.2 b||£3.2 b|
Revenue growth, %
Cost of sales
|£724.8 m||£797.5 m||£784.4 m|
Operating expense total
|£1.6 b||£1.9 b||£2 b|
Training Provided (no. of people)